NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Forecast, Price & News $3.80 +0.19 (+5.26%) (As of 09:50 AM ET) Add Compare Share Share Today's Range$3.61▼$3.8050-Day Range$2.98▼$4.4352-Week Range$2.19▼$5.80Volume8,448 shsAverage Volume163,159 shsMarket Capitalization$94.09 millionP/E RatioN/ADividend YieldN/APrice Target$38.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Abeona Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside952.6% Upside$38.00 Price TargetShort InterestHealthy2.17% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment1.08Based on 3 Articles This WeekInsider TradingAcquiring Shares$11,400 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.99) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector132nd out of 965 stocksPharmaceutical Preparations Industry44th out of 451 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Abeona Therapeutics has a forecasted upside of 952.6% from its current price of $3.61.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.17% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 13.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 3.9 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Abeona Therapeutics this week, compared to 1 article on an average week.Search Interest17 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 240% compared to the previous 30 days.MarketBeat Follows4 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions43.97% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($1.99) to ($1.77) per share.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Abeona Therapeutics (NASDAQ:ABEO) StockAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More ABEO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABEO Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.com3 Biotech Blockbusters to Turn $5,000 Into $50,000September 17, 2023 | americanbankingnews.comAbeona Therapeutics Inc (NASDAQ:ABEO) Sees Large Increase in Short InterestSeptember 22, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 14, 2023 | americanbankingnews.comAbeona Therapeutics (NASDAQ:ABEO) Shares Cross Above 50-Day Moving Average of $3.75September 12, 2023 | finance.yahoo.comAbeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial OfficerSeptember 5, 2023 | finance.yahoo.comWhile institutions own 25% of Abeona Therapeutics Inc. (NASDAQ:ABEO), retail investors are its largest shareholders with 51% ownershipAugust 30, 2023 | markets.businessinsider.comAbeona Therapeutics Plans To Proceed With BLA Submission To FDA For EB-101; Stock Up In Pre-marketAugust 30, 2023 | finance.yahoo.comAbeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA SubmissionSeptember 22, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 11, 2023 | finance.yahoo.comABEO: On Track to File BLA in 3Q23...August 8, 2023 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comAbeona Therapeutics GAAP EPS of -$0.92 misses by $0.25, revenue of $3.5MAugust 8, 2023 | finance.yahoo.comAbeona Therapeutics Reports Second Quarter 2023 Financial ResultsJuly 29, 2023 | seekingalpha.comAbeona spikes after regulatory update on lead programJuly 28, 2023 | marketwatch.comAbeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDAJuly 28, 2023 | finance.yahoo.comAbeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023July 19, 2023 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Joins Rare Disease Company CoalitionJuly 19, 2023 | finance.yahoo.comAbeona Therapeutics Joins Rare Disease Company CoalitionJuly 13, 2023 | benzinga.comCantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $38 Price TargetJuly 7, 2023 | finance.yahoo.comAbeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 3, 2023 | marketwatch.comAbeona Therapeutics Shares Rise 9% After At-the-Market Direct OfferingJuly 3, 2023 | benzinga.comAbeona Therapeutics Announces $25M Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJuly 3, 2023 | finance.yahoo.comAbeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJune 9, 2023 | marketwatch.comAbeona Therapeutics Shares Drop 7% After FDA Feedback for EB-101 BLAJune 9, 2023 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101June 9, 2023 | marketwatch.comAbeona Therapeutics Gets FDA Feedback for EB-101 BLAJune 9, 2023 | finance.yahoo.comAbeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101See More Headlines Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Company Calendar Last Earnings8/08/2023Today9/22/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$38.00 High Stock Price Forecast$38.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+952.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,700,000.00 Net MarginsN/A Pretax Margin-1,101.91% Return on Equity-174.71% Return on Assets-58.49% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.67 Sales & Book Value Annual Sales$1.41 million Price / Sales63.39 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book2.31Miscellaneous Outstanding Shares24,760,000Free Float23,939,000Market Cap$89.38 million OptionableOptionable Beta1.29 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsChimerixNASDAQ:CMRXBriaCell TherapeuticsNASDAQ:BCTXEvelo BiosciencesNASDAQ:EVLOGlycoMimeticsNASDAQ:GLYCBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInsiders & InstitutionsBrendan M O'malleyBought 3,000 shares on 9/18/2023Total: $11,400.00 ($3.80/share)Point72 Asset Management L.P.Sold 19,225 shares on 8/15/2023Ownership: 6.025%Goldman Sachs Group Inc.Bought 50,008 shares on 8/15/2023Ownership: 1.136%State Street CorpBought 7,800 shares on 8/14/2023Ownership: 0.272%Geode Capital Management LLCSold 24,895 shares on 8/11/2023Ownership: 0.839%View All Insider TransactionsView All Institutional Transactions ABEO Stock - Frequently Asked Questions Should I buy or sell Abeona Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks. What is Abeona Therapeutics' stock price forecast for 2023? 1 brokers have issued 1-year price targets for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $38.00 to $38.00. On average, they expect the company's stock price to reach $38.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts. How have ABEO shares performed in 2023? Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has increased by 17.2% and is now trading at $3.61. View the best growth stocks for 2023 here. Are investors shorting Abeona Therapeutics? Abeona Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 500,500 shares, an increase of 13.2% from the August 15th total of 442,000 shares. Based on an average trading volume of 166,400 shares, the short-interest ratio is presently 3.0 days. Approximately 2.2% of the shares of the company are sold short. View Abeona Therapeutics' Short Interest. When is Abeona Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ABEO earnings forecast. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.22. The biopharmaceutical company had revenue of $3.50 million for the quarter. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). What is Abeona Therapeutics' stock symbol? Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO." Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.02%), Goldman Sachs Group Inc. (1.14%), Citigroup Inc. (1.06%), Geode Capital Management LLC (0.84%), BlackRock Inc. (0.76%) and Northern Trust Corp (0.55%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Abeona Therapeutics' stock price today? One share of ABEO stock can currently be purchased for approximately $3.61. How much money does Abeona Therapeutics make? Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $89.38 million and generates $1.41 million in revenue each year. How can I contact Abeona Therapeutics? Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101. This page (NASDAQ:ABEO) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.